Chemomab Therapeutics Ltd (NAS:CMMB)

$ 2 -0.03 (-1.48%) Market Cap: 28.72 Mil Enterprise Value: 16.78 Mil PE Ratio: 0 PB Ratio: 2.92 GF Score: 39/100

Q1 2023 Chemomab Therapeutics Ltd Earnings Call Transcript
May 11, 2023

$1.62 (-1.52%)

Earnings
Chemomab Therapeutics Ltd at Aegis Virtual Conference Transcript
May 03, 2023
Chemomab Therapeutics Ltd at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 15, 2023
Q3 2022 Chemomab Therapeutics Ltd Earnings Call Transcript
Nov 11, 2022

$2.08

Earnings
Q2 2022 Chemomab Therapeutics Ltd Earnings Call Transcript
Aug 12, 2022

$4 (+7.24%)

Earnings
Chemomab Therapeutics Ltd at JMP Securities Life Sciences Conference Transcript
Jun 16, 2022
Q1 2022 Chemomab Therapeutics Ltd Earnings Call Transcript
May 12, 2022

$2.58 (-0.96%)

Earnings
Q4 2021 Chemomab Therapeutics Ltd Earnings Call Transcript
Mar 09, 2022

$3.79 (+4.41%)

Earnings

Q1 2023 Chemomab Therapeutics Ltd Earnings Call Transcript

May 11, 2023 / 12:00PM GMT

Release Date Price: $1.62 (-1.52%)

Transcript 8-K10-Q

Operator

Greetings, and welcome to Chemomab Therapeutics first-quarter 2023 earnings call and corporate update. (Operators Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Barbara Lindheim, Consulting Vice President of Strategic Communications. Thank you. You may begin.

Barbara Lindheim

Chemomab Therapeutics, Ltd. - IR

Welcome to the Chemomab Therapeutics 2023 first-quarter conference call. Thank you for attending. I am Barbara Lindheim, Consulting Vice President of Strategic Communications at Chemomab. With me today are Dale Pfost, our Chairman and CEO; Don Marvin, CFO, Chief Operating Officer, and Executive Vice President; Dr. Adi Mor, our Co-Founder and Chief Scientific Officer; and Dr. Matt Frankel, our Chief Medical Officer.

Before turning the call over to Dale, please take note of our forward-looking statements. Today's call may contain forward-looking statements, which may be identified by words such as may, could, will, expect, intend, plan, and other similar words and expressions.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.